Effect of Bariatric Surgery on Diagnosed Chronic Kidney Disease and Cardiovascular Events in Patients with Insulin-treated Type 2 Diabetes: a Retrospective Cohort Study from a Large UK Primary Care Database

Mohammed Alkharaiji1,2 · Uchenna Anyanwagu1 · Richard Donnelly1 · Iskandar Idris1

© The Author(s) 2020

Abstract

Aims To compare the effect of bariatric surgery on renal, chronic kidney disease (CKD) and cardiovascular (CV) outcomes among obese patients with insulin-treated type 2 diabetes (T2D) with and without microalbuminuria (i.e., uACR > 3.0 mg/mmol).

Methods A retrospective cohort study was conducted among 11,125 active patients with T2D from The Health Improvement Network (THIN) database. Propensity score matching (up to 1:6 ratio) was used to identify patients who underwent bariatric surgery (N = 131) with a non-bariatric cohort (N = 579). Follow-up was undertaken for 10 years (6487 person-years) to compare differences in risk of cardiovascular events and in renal outcomes.

Results For the matched cohort at baseline: mean age 52 ± 13 years (60% female); weight 116 ± 25 kg, body mass index (BMI) 41 ± 9 kg/m², estimated glomerular filtration rate (eGFR); 70.4 ± 20 mL/min/1.73 m², and median albumin-creatinine ratio (uACR) 2.0 mg/mmol (interquartile range (IQR): 0.9–5.2 mg/mmol). Bariatric surgery was associated with a 54% reduction in developing CKD compared to their matched non-bariatric cohort (adjusted hazard ratio [aHR]: 0.46; 95%CI: 0.24–0.85, P = 0.02). Among patients with microalbuminuria at baseline, bariatric surgery was protective against CKD (aHR: 0.42, 95%CI: 0.18–0.99, P = 0.050). eGFR was significantly increased from baseline favouring the bariatric group during 75% of the follow-up time (calculated mean difference between groups: 4.1 mL/min/1.73 m²; P < 0.05), especially at 5-year point (74.2 vs 67.8 mL/min/1.73 m²; P < 0.001). However, no significant change was observed with non-fatal CVD episodes (aHR: 0.36, 95%CI: 0.11–1.13, P = 0.079). Albumin levels were significantly reduced throughout the 2 years following the surgery (3.9 vs 4.1 g/dL, P < 0.001). uACR and total protein levels had little or no statistical association to the intervention.

Conclusion Bariatric surgery may protect patients with diabetes with or without microalbuminuria against the risk of CKD and with a modest protective effect on non-fatal CVD risk. Bariatric surgery is also associated with improvements in overall renal outcomes such as eGFR.

Keywords Bariatric · Diabetes · Kidney · Renal · CKD · Microalbuminuria · Obesity · Cardiovascular
many patients with T2D will require insulin treatment to control hyperglycemia. This is relevant within the context of diabetic kidney disease since insulin therapy is known to induce ~ 4–9 kg weight gain in the first year of treatment [4] while obesity per se is a significant risk factor for the appearance of proteinuria and ESRD [2]. Further, recent evidence from randomised controlled trials, epidemiological and observational studies have implicated insulin therapy in patients with T2D with increased CV risk and mortality [5–8]. Thus, a cohort of insulin-treated patients with T2D represents a complex heterogenous, challenging group of patients, many of whom have significant comorbidities and high CKD risk. CKD is defined as an estimated glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m² or the presence of increased urinary albumin excretion (microalbuminuria), indicated by urine albumin-to-creatinine ratio (uACR) of 3.0–30.0 mg/mmol, or overt proteinuria (uACR > 30.0 mg/mmol), all of which are independent risk factors for CV and kidney disorders in the general population and in patients with diabetes [9]. Thus, weight loss by any means is important to improve cardio-renal outcomes [10]. Although diet and exercise play a crucial role in obesity management, lifestyle alone may not achieve durable weight loss in the majority of patients [11]. Bariatric surgery, therefore, has emerged as the most effective and durable strategy for long-term weight loss in morbidly obese individuals [12].

Despite the clear benefits of bariatric surgery on weight and glycemic outcomes in people with T2D, the impact of bariatric surgery on the development and progression of CKD or micro-albuminuria is less clear. Previous studies have reported improvements in uACR [13–16], which can be observed not long after surgery [15, 16]. This is thought to be driven by multi-factorial improvements in blood pressure, HbA1c and BMI [15]. A further study concluded that bariatric surgery should be offered as an early treatment for patients with microalbuminuria or with overt proteinuria to prevent CKD from progressing to an end-stage kidney disease (ESKD) [17]. However, many of these studies were either small case series, not specific to people with insulin-treated diabetes, had variable albuminuric state at baseline, or did not adjust for important confounders. Conversely, inconsistent findings were reported in a systematic review of the effects of bariatric surgery on renal outcomes by Zhou et al [18], with some studies also noting harmful effects on kidneys of obese patients who received bariatric intervention. For example, there may be an increased risk of kidney stones after malabsorptive bariatric surgery, which is considered to be linked with surgery-induced fat malabsorption [19]. Furthermore, despite weight benefits, there are negative metabolic outcomes related to bariatric intervention, such as nutritional deficiencies, reduction in lean body mass and bone density loss, all of which are highly relevant in patients with CKD [20].

This study aims to retrospectively explore the possible preventive effect of bariatric surgery against CKD, renal-cardiovascular, as well as impact on health and renal outcomes in patients with and without microalbuminuria (i.e., uACR > 3.0 mg/mmol).

**Methods**

**Study Design and Data Sources**

This was a retrospective cohort study that used The Health Improvement Network (THIN), a UK primary care database with systematically computerised longitudinal and anonymised health records from primary care physicians. The database contains details on demographics, lifestyle characteristics (e.g. alcohol use and smoking), major medical and surgical conditions, drug utilisation and various health outcomes of over 17 million patients, 3.1 million of which are registered as active patients. Patients’ records were derived from over 600 UK general practices [21]. The dataset slice we acquired has information of active patients with insulin-treated type 2 diabetes up to September 2017. Ethics approval was provided to THIN by the NHS South East Multi-Centre Research Ethics Committee (MREC). The Scientific Review Committee (SRC) reviewed the study protocol for scientific merit and feasibility.

**Study Population**

The dataset contains 11,125 adult patients (18 years and over with no upper age limit) diagnosed with T2D who had been prescribed with any form of insulin therapy up to September 2017. Patients’ index date was based on either the day of bariatric surgery or, in case they had not received bariatric intervention, the first intensification of insulin therapy. The study was exposure-based, in which patients were censored throughout 10 years of follow-up—following the development of primary outcome, transferred out, loss to follow-up, or at the end of the study. Primary outcomes were patients’ survivability against diagnosed CKD events, with further stratification to include CKD and CVD events, from a population of patients with microalbuminuria (uACR > 3 mg/mmol) at baseline. The risk of CKD was measured according to observed CKD data that were reported with specific dates in
the main THIN database. The CKD events were assessed and reported by health professionals according to the medical criteria used across the NHS primary health provision (GFR < 60 or ACR > 3.5) and covered by the THIN database collection system. The crude CVD events included the first occurrence of either acute myocardial infarction, stroke, coronary heart disease, heart failure, or peripheral artery disease. Observations of CVD events were obtained in a similar manner as with events of CKD reporting system prearranged by THIN. Secondary outcomes included likelihood of being improved in eGFR, as well as health covariates, such as levels of uACR, total protein, albumin and serum creatinine.

Covariates and Follow-up Strategy

The treatment group, those undergoing bariatric surgery and being insulin-treated T2D from the date of surgery, was followed up and compared with their propensity-score (PS)-matched insulin initiators from their first insulin prescription date up to the endpoint of the 10-year follow-up period. Patients with diagnosed CKD or whose CVD events occurred prior to the designated baseline point were excluded from the primary survival estimation on each stratified element.

The baseline clinical parameters were measured at a similar point of time according to patient’s treatment category. Patients who underwent bariatric surgery, for instance, will have their baseline parameters calculated\(^1\) from 90 days up to 1 day before the surgery date. Similarly, the non-bariatric patients will have their baseline parameters calculated via the same time window according to their first intensification of insulin therapy. Covariates were, then, recalculated at 6 months, and at each year point during follow-up, with a 90-day window on every concurring point of time.

Statistical Analysis

Primary analysis was time to the risk of crude CKD events and stratified CKD and CVD events in the PS-matched groups. The PS model was estimated by using a logistic regression model in order to adjust for baseline characteristics, thus, minimising allocation bias between groups. The balance assessment was made between bariatric (treated) and non-bariatric (untreated) groups by measuring standardised differences before and after the matching procedure. The mean from continuous covariates and proportion of categorical variables between groups were examined and summarised. Each treatment subject was matched to a maximum number of six reference subjects at the nearest distance measured by the estimated PS, based on the estimated treatment probabilities [22]. Furthermore, in order to minimise distance within matched sets, we employed calliper of width equal to 0.05 of the standard deviation of the logit of the PS, which may improve match quality and also limited excessive numbers of matched subjects [23]. A calliper of width of 0.2 or lower was shown in recent research to result in optimal estimation compared to higher choices of calliper use [24]. PS was included in all Cox proportional hazards regression modelling as it was considered a prognostic covariate.

We used the stratified log-rank test, with Kaplan-Meier survival curves, respectively, to compare the equality between the PS-matched groups. The absolute reduction in the probability of an event occurring within 10-year follow-up was, thus, calculated. Marginal hazard ratios were also estimated, which allowed the quantification of the adjusted hazard of an event occurring in the bariatric group compared to the matched non-bariatric group. Proportional hazards assumptions were confirmed through Schoenfeld residual test. Point estimates with 95% confidence intervals (CIs) at the conventional statistical significance level of 0.05 were used in the regression models. The proportional hazards assumption was examined by comparing the cumulative hazard plots grouped on exposure; no violations were observed.

Missing data among covariates were managed through multiple imputations using the predictive means matching for continuous covariates with accounting to exposure (i.e. bariatric), age, gender, diabetes duration, Townsend deprivation status, marital status, smoking and alcohol use [25]. To test the adequacy of our multiple imputation approach in addressing the impact of some missing data, we conducted a sensitivity analysis wherein the primary endpoints in the imputed dataset were compared with the dataset with missing values and found to be similar up to 2 years of follow-up. This affirmed the robustness of the imputation method employed before PS matching procedure was performed [26].

We used Student’s \(t\) test to estimate the mean changes in continuous variables (e.g. uACR and total protein) in the PS-matched group for 2 years of follow-up compared to their baseline measurements. We limited these variables to 2 years due to the heavy load of missing data beyond this point, which restricted multiple imputation from producing reliable predictions. Nonetheless, eGFR was at a predictable level up to 5 years, which made it possible to run Pearson \(X^2\) to test the likelihood of being improved throughout 5 years from the baseline. Wilcoxon rank-sum test was used to check differences in medians for nonparametric variables (i.e. uACR). Statistical significance was set at a \(p\) level of 0.05. To avoid the probability of type II error, the study was powered to 0.86 and the matched sample size of 710 was found to detect a true difference of less than 0.1 between the two groups at 5% significance level. The study fulfilled the STROBE criteria for reporting observational studies. Throughout, we used SAS Software version 9.4 in the initial dataset management (SAS Institute, Cary, NC); Stata/SE Statistical Software.

---

\(^1\) Average value is calculated for multiple entry records that were found during the 90 days window for the same variable.
version 15.1 in all carried analysis (StataCorp., College Station, TX); and GraphPad/Prism version 8.1.0 for visualisation (La Jolla, CA).

Results

Patients’ Characteristics and Total Follow-up

From a total population of 11,125 patients with insulin-treated T2D in THIN database, we identified 155 patients who have had Roux-Y-gastric bypass surgical operations. The PS matching procedure has allowed (131) bariatric patients to be matched with up to six control subjects (579). This yielded a total number of 710 PS-matched participants. The median treatment duration was 10.07 years (interquartile range (IQR): 6.11–14.31 years). The median follow-up was 12.8 years (IQR: 5.1–14.5 years) for the matched cohort, representing a total follow-up period of 6487 person-years.

The mean age for the matched groups at baseline was 51.7 (SD 12.5) years; 59.6% were females. The mean body weight, BMI and HbA1c level were 115.7 (SD 25.4) kg, 40.7 (SD 9.2) kg/m² and 71.2 (SD 18.1) mmol/mol, respectively. The mean eGFR was 70.4 (SD 20.5) mL/min/1.73 m², with a median uACR of 2.0 (IQR: 0.9–5.2) mg/mmol. The baseline characteristics in both bariatric and non-bariatric groups were compared between the full and matched cohort with respective standardised differences and are shown in Table 1.

Probability of Survival and Event Rate

The probability of survival for CKD in the full cohort was significantly different between bariatric and non-bariatric groups: at 1 year (99.2% vs 97.7%), 5 years (96.9% vs 89.9%) and 10 years (94.9% vs 80.2%) of follow-up (log-rank test $p$ value = 0.028). However, the estimates of CKD event rate in the unadjusted PS matched cohort showed little or no statistical significance of a difference throughout 10 years of follow-up (log-rank test $p$ value = 0.028). A total of 119 CKD events were observed (16 vs 103) with a crude event rate of 55.0 (49.5 vs 56.9) per 1000 person-years (95%CI: 40.8–74.2). Figure 1 and Table 2 summarise the observed events, event rates and differences in the probability of survival.

Risk of CKD

Bariatric surgery showed remarkable protective effect against crude CKD in the full cohort and in the adjusted matched group. In the full cohort, patients whom had been treated with bariatric surgery had 47% lower risk to develop CKD compared to non-bariatric patients (adjusted hazard ratio (aHR): 0.53, 95%CI: 0.30–0.91, $P = 0.021$). Similarly, the matched cohort showed a statistical significance of a magnitude favouring the bariatric group with a protective effect of 54% against crude CKD risk (aHR: 0.46, 95%CI: 0.24–0.85, $P = 0.013$). Table 2A shows a summary of adjusted and unadjusted hazard ratios in crude CKD risk for matched and unmatched patient groups.

Risk of CKD in Patients with Microalbuminuria

Despite a protective tendency against CKD, patients with microalbuminuria at baseline have little or no statistical evidence of a similar protective effect in the full cohort (aHR: 0.71, 95%CI: 0.33–1.5, $P = 0.38$). However, the estimates imply a protective influence against CKD favouring the bariatric group in the matched cohort (aHR: 0.42, 95%CI: 0.18–0.99, $P = 0.050$). The adjustments made for this model have only omitted 13.2% of observed events. Table 2B shows a summary of adjusted and unadjusted hazard ratios in CKD risk for patients with microalbuminuria.

Risk of CVD in Patients with Microalbuminuria

In the full cohort, patients with microalbuminuria, who had been treated with bariatric surgery, had a 70% lower risk in developing CVD (aHR: 0.30, 95%CI: 0.18–0.96, $P = 0.043$). The added adjustments for this model have omitted 37.1% out of the unadjusted model. However, these adjustments helped to reveal evidence of little or no statistical effect of such protection against CVD in the matched cohort (aHR: 0.36, 95%CI: 0.11–1.13, $P = 0.079$). Table 2C shows a summary of adjusted and unadjusted hazard ratios in CVD risk for patients with microalbuminuria.

Change in Secondary Outcome Variables

Significant reductions in the matched cohort (i.e. $P < 0.001$) favouring the bariatric group vs non-bariatric were observed in terms of body weight and BMI throughout 5 years of follow-up time compared to baseline. Body weight and BMI...
| Baseline variable                  | Cohort | Bariatric [n = 155] | Non-bariatric [n = 10,970] | Std. diffa | Bariatric [n = 131] | Non-bariatric [n = 579] | Std. diffb |
|----------------------------------|--------|---------------------|-----------------------------|-----------|---------------------|-------------------------|-----------|
| **Demographics**                 |        |                     |                             |           |                     |                         |           |
| Age (years), mean (SD)           |        | 50.01 (11.1)        | 57.71 (13.3)                | -0.694    | 50.74 (11.0)        | 51.96 (12.8)            | -0.110    |
| Gender, no (%)                   |        | 89 (57.4)           | 5068 (46.2)                 | 0.224     | 73 (55.4)           | 351 (60.6)              | -0.107    |
| Townsend deprivation, %          |        |                     |                             |           |                     |                         |           |
| Least deprived                   |        | 14.0                | 21.7                        | -0.204    | 15.7                | 17.3                    | -0.044    |
| Less                             |        | 24.3                | 20.7                        | 0.086     | 24.0                | 18.1                    | 0.145     |
| Average                          |        | 17.6                | 21.4                        | -0.094    | 16.5                | 20.2                    | -0.094    |
| More                             |        | 20.6                | 20.9                        | -0.008    | 21.5                | 27.7                    | -0.144    |
| Most deprived                    |        | 23.5                | 15.3                        | 0.209     | 22.3                | 16.8                    | 0.14      |
| **Type 2 diabetes (years), mean (SD)** |        |                     |                             |           |                     |                         |           |
| Diabetes duration                |        | 14.15 (7.7)         | 15.12 (8.4)                 | -0.125    | 13.97 (7.8)         | 14.89 (7.6)             | -0.117    |
| Insulin dependency               |        | 6.97 (4.9)          | 7.99 (5.5)                  | -0.208    | 7.13 (4.9)          | 8.55 (5.6)              | -0.289    |
| **Drug use duration (years), mean (SD)** |        |                     |                             |           |                     |                         |           |
| Oral antidiabetics               |        | 11.61 (5.8)         | 10.77 (6.1)                 | 0.145     | 11.89 (5.7)         | 11.26 (5.7)             | 0.110     |
| Antihypertensive                 |        | 12.69 (6.6)         | 12.21 (6.6)                 | 0.074     | 12.89 (6.7)         | 12.25 (6.3)             | 0.095     |
| Diuretics                        |        | 8.22 (7.3)          | 8.99 (7.0)                  | -0.105    | 8.09 (7.3)          | 9.32 (7.1)              | -0.168    |
| Aspirin                          |        | 8.34 (5.7)          | 8.69 (5.4)                  | -0.061    | 8.64 (5.9)          | 8.25 (5.4)              | 0.066     |
| **Clinical parameters, mean (SD)** |        |                     |                             |           |                     |                         |           |
| Weight (kg)                      |        | 127.3 (30.3)        | 90.79 (20.6)                | 1.204     | 123.22 (28.3)       | 114.88 (24.5)           | 0.294     |
| Height (m)                       |        | 1.7 (0.1)           | 1.68 (0.1)                  | 0.201     | 1.7 (0.1)           | 1.69 (0.1)              | 0.102     |
| BMI (kg/m²)                      |        | 43.87 (10.0)        | 32.37 (7.5)                 | 1.150     | 42.77 (9.6)         | 40.6 (9.0)              | 0.226     |
| Fasting glucose (mmol/L)         |        | 9.83 (4.3)          | 9.93 (3.9)                  | -0.023    | 9.84 (4.3)          | 9.82 (3.9)              | 0.004     |
| Blood glucose (mmol/L)           |        | 12.22 (8.8)         | 11.69 (5.3)                 | 0.071     | 12.04 (9.1)         | 11.92 (5.3)             | 0.016     |
| SBP (mmHg)                       |        | 134.64 (14.6)       | 138.89 (16.5)               | -0.271    | 135.06 (14.5)       | 136.4 (16.0)            | -0.088    |
| DBP (mmHg)                       |        | 78.66 (8.4)         | 78.94 (9.6)                 | -0.031    | 79.3 (8.5)          | 78.77 (9.3)             | 0.058     |
| Albumin (g/dL)                   |        | 3.96 (0.4)          | 4.15 (0.5)                  | -0.368    | 3.96 (0.4)          | 3.96 (0.4)              | 0.005     |
| Alkaline phosphatase (IU/L)      |        | 98.31 (47.1)        | 91.62 (43.0)                | 0.146     | 98.79 (48.8)        | 96.88 (51.5)            | 0.038     |
| Serum creatinine (µmol/L)        |        | 91.74 (78.4)        | 92.68 (52.6)                | -0.014    | 92.29 (84.0)        | 88.17 (57.7)            | 0.056     |
| Triglyceride (mmol/L)            |        | 2.33 (1.5)          | 2.03 (1.3)                  | 0.2       | 2.34 (1.6)          | 2.44 (1.0)              | 0.049     |
| Total cholesterol (mmol/L)       |        | 4.47 (1.2)          | 4.49 (1.1)                  | -0.019    | 4.52 (1.2)          | 4.52 (1.2)              | 0.002     |
| Low density lipoprotein (mmol/L) |        | 2.39 (0.9)          | 2.39 (0.9)                  | 0.001     | 2.39 (0.9)          | 2.44 (1.0)              | -0.05     |
| High density lipoprotein (mmol/L)|        | 1.07 (0.3)          | 1.22 (0.4)                  | -0.439    | 1.07 (0.3)          | 1.1 (0.3)               | -0.091    |
| **Alcohol status, %**            |        |                     |                             |           |                     |                         |           |
| Unknown                          |        | 3.7                 | 3.1                         | 0.03      | 3.3                 | 3.0                     | 0.017     |
| Ex-drinker                       |        | 11.8                | 7.0                         | 0.162     | 11.6                | 11.5                    | 0.003     |
| Never                            |        | 33.1                | 31.3                        | 0.039     | 33.1                | 33.1                    | -0.002    |
| Current                          |        | 51.5                | 58.5                        | -0.143    | 52.1                | 52.4                    | -0.006    |
| **Smoking status, %**            |        |                     |                             |           |                     |                         |           |
| Ex-smoker                        |        | 33.1                | 37.1                        | -0.085    | 31.4                | 36.9                    | -0.116    |
| Never                            |        | 52.9                | 49.7                        | 0.064     | 52.9                | 52.2                    | 0.015     |
| Current                          |        | 14.0                | 13.1                        | 0.025     | 15.7                | 10.9                    | 0.141     |
| **Comorbidities, %**             |        |                     |                             |           |                     |                         |           |
| Hypoglycaemia                    |        | 32.4                | 29.9                        | 0.054     | 31.3                | 26.1                    | 0.116     |
for bariatric vs non-bariatric were at 1-year point (97.5 ± 24.2 vs 109.8 ± 18.6 kg; 33.5 ± 7.4 vs 38.3 kg/m², respectively), at 3-year point (95.7 ± 19.4 vs 108.8 ± 18.4 kg; 33.5 ± 7.4 vs 38.3 kg/m², respectively) and at 5-year point (98.9 ± 23.3 vs 107.1 ± 18.2 kg; 34.2 ± 9.0 vs 38.8 ± 7.4 kg/m², respectively).

The nonparametric tests for the uACR medians revealed little or no statistical significance of a difference between bariatric and non-bariatric groups in both matched and full cohorts. In the full cohort, the median uACR in bariatric group at baseline was 2.0 vs 1.91 mg/mmol in non-bariatric (Z = −1.28, P = 0.19), at 1-year point 2.33 vs 1.90 mg/mmol (Z = −1.86, P = 0.06), and at 2-year point 2.42 vs 2.06 mg/mmol (Z = −0.87, P = 0.38), respectively. In the matched cohort, the median uACR in the bariatric group at baseline was 2.03 vs 1.90 mg/mmol in the non-bariatric group (Z = −1.75, P = 0.08), at 1-year point 2.31 vs 1.95 mg/mmol (Z = −1.36, P = 0.17) and at 2-year point 2.42 vs 2.02 mg/mmol (Z = −0.67, P = 0.50), respectively.

There have been significant improvements in eGFR throughout 5 years of follow-up favouring the bariatric group in both full and matched cohorts. In the matched cohort, the eGFR was at similar levels at baseline with a mean of 68.7 in bariatric patients vs 70.8 mL/min/1.73 m² in non-bariatric (t_{708} = 1.05, P = 0.29). Mean eGFR for the bariatric compared with non-bariatric group were 72.4 vs 68.4 mL/min/1.73 m² (t_{708} = −2.07, P = 0.038) at 1 year and 71.4 vs 68.4 mL/min/1.73 m² (t_{708} = −1.48, P = 0.13) at 3 years. However, during the fourth and fifth years of follow-up, the analysis of mean differences reported statistical significance favouring the bariatric group versus non-bariatric with 72.9 vs 66.8 mL/min/1.73 m² at 4-year point (t_{708} = −3.14, P = 0.001) and with 74.2 vs 67.8 mL/min/1.73 m² at 5-year point, respectively. Figure 3 illustrates proportions of both bariatric and non-bariatric patients with eGFR more than 60 mL/min/1.73 m² during 5 years of follow-up. The serum creatinine was also significantly reduced in the bariatric group compared to their matched non-bariatric counterparts during the 2 years of follow-up—following the baseline point. Both groups were at similar levels of serum creatinine at baseline with a mean of 90.1 (SD 84.1) µmol/L in bariatric versus 88.4 (SD 57.7) µmol/L non-bariatric (t_{708} = −0.27, P = 0.78). Mean creatinine for the bariatric group vs non bariatric was 79.7 vs 91.2 µmol/L (t_{708} = 2.59, P = 0.009) at 6 months, 78.4 vs 86.1 µmol/L (t_{708} = 2.11, P = 0.03) at 1-year point, and 77.2 vs 90.5 µmol/L at 2-year point (t_{708} = 2.65, P = 0.008) (Fig. 2c).

In the matched cohort, the bariatric group had significantly lower albumin levels compared to non-bariatric throughout 2 years of follow-up. The total protein level showed a slight clinical change with a statistically significant difference at 1-year point, but with no difference detected in all other points of follow-up time. Figure 2 shows mean differences between the matched groups while reflecting back to baseline observations for (a) total protein and (b) blood albumin.

**Discussion**

This study focused on severely obese patients with insulin-treated T2D and noted that there is a relationship between bariatric surgical intervention and protective effect against CKD and observed improvements in overall patients’ renal outcomes, with benefits reaching patients with or without microalbuminuria at baseline. Despite the matched cohort showing little or no statistical significance regarding protection against the risk of non-fatal CVD, the estimates following the surgery suggest a positive influence with lower event rate favouring the bariatric group. The survival analysis on full cohort also indicated a profound effect protecting microalbuminuria patients who had received bariatric surgery.

---

**Table 1** (continued)

| Table 1 | Cohort | Full population [N = 11,125] | Propensity matched [N = 710] |
|---------|--------|-----------------------------|-----------------------------|
| NAFLD\(^c\) | 4.7    | 3.0                         | 4.6                         | 2.8                         | 0.097                        |
| Anaemia  | 15.5   | 12.2                        | 16.8                        | 13.3                        | 0.098                        |
| Acute myocardial infarction | 24.3    | 20.3                        | 23.1                        | 20.2                        | 0.073                        |
| Stroke   | 11.0   | 12.9                        | −0.059                      | 12.4                        | 7.7                          | 0.156                        |
| Heart failure | 18.4    | 17.8                        | 0.016                       | 17.4                        | 18.5                         | −0.029                       |

Diabetes duration is time from first diagnosis of diabetes to date of intensification with insulin drug (index date)

*Standardised differences are the absolute difference in means or percentages divided by the SD of the treated group. Resulting standardised difference after 1:6 matching based on average treatment effect on treated propensity score technique and robust variance estimation*

*Mean of standardized difference after matching (0.081), i.e. at 8% difference measured between the matched groups*

*Non-alcoholic fatty liver disease*
Fig. 1 Bariatric vs. non-bariatric Kaplan-Meier survival analysis plots for diagnosed CKD events in a full and b matched cohorts, diagnosed CKD events in patients with microalbuminuria (i.e. uACR > 3 mg/mmol) at baseline in c full and d matched cohorts, and crude CVD events in patients with microalbuminuria at baseline in both e full and f matched cohorts throughout 10 years of follow-up.
intervention treatment concerning crude non-fatal CVD
events. An overall improvement in the bariatric matched
group regarding eGFR levels was also noted throughout 5
years of follow-up (Fig. 3).

We believe our findings are robust. A review of previously
published studies has shown that we utilised a relatively novel
approach that included an indirect assessment of time-to-event
based on baseline patients’ renal status. This timely phase
involved full, as well as the PS-matched cohorts, being allo-
cated into further stratifications, leading to proper follow-up
for survival investigation. In this approach, the bariatric sur-
gical intervention provides additional evidence of a protective
effect benefiting T2D patients with or without detected
microalbuminuria at baseline.

Obesity is associated with glomerular hyperfiltration, and
therefore increased risk of microalbuminuria and/or protein-
uria in patients with or without renal disease [27, 28]. Previous
studies have shown that bariatric surgery is associated with a
reduction in glomerular hyperfiltration [29, 30] which mainly
occurred in the first year after surgery being associated with
the greatest period of weight loss. The link between fat mass
and glomerular hyperfiltration is multifactorial, but partly due
to increase of angiotensin II (AngII), which enhances tubular
sodium reabsorption and activates tubulo-glomerular feedback
[31], leading to vasodilation of the afferent arterioles,
with a consequent increase in renal blood flow, intra-
glomerular pressure and eGFR [28, 29]. However, while
reductions in glomerular hyperfiltration may induce reduc-
tions in microalbuminuria and proteinuria levels, eGFR is ex-
pected to reduce [32]. There is limited knowledge concerning
the longer-term effect of bariatric surgery on eGFR and CKD
outcomes in patients with insulin-treated T2D. We have spe-
cifically investigated this patient cohort due to the negative
effects of insulin on weight [4], a known predictor of adverse
renal outcomes, as well as the fact that this group of patients
are already at high risk of adverse-cardio-renal outcomes
[5–8]. In addition, patients with diabetes are associated with
accelerated loss of lean muscle mass [33], while bariatric sur-
urgery is associated with further loss of muscle mass and func-
tion [34]. Since markers of both muscle mass and strength
being important predictors of outcomes in these patients with
CKD [35], our study provided reassurance of the protective
effects of bariatric surgery against progression of CKD.

The main strength of our study derives from the inclusion
of a relatively large cohort of patients with T2D receiving
insulin therapy who underwent bariatric surgery in a real-
world population. In addition, our database is largely repre-
sentative of the UK population, and as such, our findings will
be generalizable to various populations that share similar dem-
ographics. The large cohort of patients studied here provides
adequate statistical power and also contains information on
other time-varying covariates to adjust for possible con-
founders. We adjusted for a large set of factors that could have
differed at baseline. Nonetheless, some residual confounding
in our study could persist. For example, our classification of
albuminuria was largely based on a single measurement, in
contrast to current recommendation, in which at least two
measurements are required. Nonetheless, a single measure of urinary albumin within a large patient cohort provides a great deal of predictive information. In addition, as is the case in all studies of CV or ESRD risk associated with eGFR and albuminuria, the effect of competing hazards may bias estimates of risk. This is because elevated ACR and low eGFR are also risk factors for non-renal diseases, associated differential mortality in high-risk individuals may confound hazard ratio estimates for CV events. Lastly, changes after baseline in medications and subsequent changes in glycaemic indices or blood
pressure were not evaluated in this analysis and, therefore, cannot account for any differences that might influence the association between ACR and outcomes.

Although bariatric surgery may protect patients who have diabetes with or without microalbuminuria against the risk of CKD, there is a modest protective effect on non-fatal CVD risk. Bariatric surgery also helps in overall improvement in renal outcomes such as eGFR. There is, however, a necessity for prospective investigation and appropriate investment for verifying or examining real-world effects of bariatric surgical intervention on renal function and stability of severely obese patients who are dependent on insulin treatment.

Compliance with Ethical Standards  Ethics approval was provided to THIN by the NHS South East Multi-Centre Research Ethics Committee (MREC). The Scientific Review Committee (SRC) reviewed the study protocol for scientific merit and feasibility.

Conflict of Interest  The authors declare that they have no conflict of interest.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011;377(9765):557–67.
2. Praga M, Morales E. Obesity, proteinuria and progression of renal failure. Current Opinion in Nephrology and Hypertension. 2006;15(5):481–6.
3. Bayes HE. Adiposopathy: is “sick fat” a cardiovascular disease? Journal of the American College of Cardiology. 2011;57(25):2461–73.
4. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes – causes, effects and coping strategies. Diabetes, Obesity and Metabolism. 2007;9(6):799–812.
5. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 Diabetes. New England Journal of Medicine. 2008;358(24, 2545):–59.
6. Van Avendonk MWJ, Rutten GEH. Insulin therapy in type 2 diabetes; what is the evidence? Diabetes. Obesity and Metabolism. 2009;11(5):415–32.
7. Currie CJ, Poole CD, Evans M, et al. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. Journal of Clinical Endocrinology & Metabolism. 2013;98(2):668–77.
8. Roumie CL, Greevy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. Journal of the American Medical Association. 2014;311(22):2288–96.
9. Levey AS, De Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney International. 2011;80(1):17–28.
10. Vidal J. Updated review on the benefits of weight loss. International Journal of Obesity Related Metabolic Disorders. 2002;26(Suppl 4): S25–8.
11. Dombrowski SU, Knittle K, Avenell A, et al. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. British Medical Journal. 2014;348:g2646.
12. Golzarand M, Toolabi K, Farid R. The bariatric surgery and weight losing: a meta-analysis in the long- and very long-term effects of laparoscopic adjustable gastric banding, laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy on weight loss in adults. Surgical Endoscopy. 2017;31(11):4331–45.
13. Stephenson DT, Jandeleit-Dahm K, Balkau B, et al. Improvement in albuminuria in patients with type 2 diabetes after laparoscopic adjustable gastric banding. Diabetes and Vascular Disease Research. 2013;10(6):514–9.
14. Li K, Zou J, Ye Z, et al. Effects of bariatric surgery on renal function in obese patients: a systematic review and meta analysis. PloS One. 2016;11(10):e0163907.
15. Miras AD, Chuah LL, Khalil N, et al. Type 2 diabetes mellitus and microvascular complications 1 year after Roux-en-Y gastric bypass: a case–control study. Diabetologia. 2015;58(7):1443–7.
16. Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. Journal of the American Medical Association. 2014;311(22):2297–304.
17. Kim EY, Kim YJ. Does bariatric surgery really prevent deterioration of renal function? Surgery for Obesity and Related Diseases. 2016;12(4):856–61.
18. Zhou X, Li L, Kwong JS, et al. Impact of bariatric surgery on renal functions in patients with type 2 diabetes: systematic review of randomized trials and observational studies. Surgery for Obesity and Related Diseases. 2016;12(10):1873–82.
19. Chang AR, Grams ME, Navaneethan SD. Bariatric surgery and in albuminuria in patients with type 2 diabetes after laparoscopic adjustable gastric banding. Diabetes and Vascular Disease Research. 2013;10(6):514–9.
20. Ben-Porat T, Weiss-Sadan A, Rottenstreich A, et al. Nutritional causes, effects and coping strategies. Diabetes, Obesity and Related Diseases. 2002;6:32.
21. The Heath Improvement Network (THIN). 2018; Available from: https://www.iqvia.com/locations/uk-and-ireland/thin.
22. Garrido MM, Kelley AS, Paris J, et al. Methods for constructing and assessing propensity scores. Health Services Research. 2014;49(5):1701–20.
23. Rassen JA, Shetlar AA, Myers J, et al. One-to-many propensity score matching in cohort studies. Pharmacoepidemiology and Drug Safety. 2012;21(S2):69–80.
24. Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. American Journal of Epidemiology. 2010;172(9):1092–7.
25. Morris TP, White IR, Royston P. Tuning multiple imputation by predictive mean matching and local residual draws. BMC Medical Research Methodology. 2014;14(1):75.
26. Eulenburg C, Suling A, Neuser P, et al. Propensity scoring after multiple imputation in a retrospective study on adjuvant radiation therapy in lymph-node positive vulvar cancer. PloS One. 2016;11(11):e0165705.

27. De Jong PE, Verhave JC, Pinto-Sietsma SJ, et al. Obesity and target organ damage: the kidney. International Journal of Obesity & Related Metabolic Disorders. 2002;26:S21–4.

28. Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. American Journal of Physiology-Renal Physiology. 278(5):F817–22.

29. Chagnac A, Weinstein T, Herman M, et al. The effects of weight loss on renal function in patients with severe obesity. Journal of the American Society of Nephrology. 2003;14(6):1480–6.

30. Serra A, Granada ML, Romero R, Bayés B, Cantón A, Bonet J, et al. The effect of bariatric surgery on adipocytokines, renal parameters and other cardiovascular risk factors in severe and very severe obesity: 1-year follow-up. Clinical Nutrition. 2006;25(3):400–408.

31. Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation and TGF-β expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney International. 1999;56(3):860–72.

32. Brochner-Mortensen J, Rickers H, Balslev I. Renal function and body composition before and after intestinal bypass operation in obese patients. Scandinavian Journal of Clinical and Laboratory Investigation. 1980;40(8):695–702.

33. Park SW, Goodpaster BH, Lee JS, et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care. 2009;32(11):1993–7.

34. Skogar M, Holmståck U, Hedberg J, et al. Preserved fat-free mass after gastric bypass and duodenal switch. Obesity Surgery. 2017;27(7):1735–40.

35. Carrero JJ, Stenvinkel P, Cuppari L, et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRN). Journal of Renal Nutrition. 2013;23(2):77–90.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.